Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
472 results about "Heat shock protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Heat shock proteins (HSP) are a family of proteins that are produced by cells in response to exposure to stressful conditions. They were first described in relation to heat shock, but are now known to also be expressed during other stresses including exposure to cold, UV light and during wound healing or tissue remodeling. Many members of this group perform chaperone functions by stabilizing new proteins to ensure correct folding or by helping to refold proteins that were damaged by the cell stress. This increase in expression is transcriptionally regulated. The dramatic upregulation of the heat shock proteins is a key part of the heat shock response and is induced primarily by heat shock factor (HSF). HSPs are found in virtually all living organisms, from bacteria to humans.
Novobiocin analogues as anticancer agents
Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.
Owner:UNIVERSITY OF KANSAS +1
Novobiocin analogues as anticancer agents
Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.
Owner:UNIVERSITY OF KANSAS +1
Sulfamoyl-containing derivatives and uses thereof
InactiveUS20080096903A1Provide effectReduce the number of cellsBiocideNervous disorderHeat shock proteinDisease cause
Sulfamoyl-containing compounds are disclosed, having utility as inhibitors of disease-related targets, such as Heat Shock Protein 90 (HSP90), and which are useful for treating disorders, e.g., proliferative disorders, including HSP90-mediated disorders. Methods for preparing and using the disclosed compounds are also described.
Owner:WYETH
Vestibular stimulation apparatus and associated methods of use
ActiveUS20100211142A1Improve ventilationDevices for heating/cooling reflex pointsAdditive manufacturing apparatusHistamine ProductionVestibular system
A device and associated method for providing vestibular stimulation to an individual includes active elements positioned on or proximate an ear insert. The active elements include but are not limited to at least one electrode, at least one thermometer, and at least one thermoelectric transducer. The device includes a computerized control module regulating the active elements. The device incorporates an ear insert that allows the active elements to engage the individual's ear canal and therefore access the individual's vestibular system. Vestibular stimulation applied to the individual is customized for directly stimulating desired regions of the brain for therapeutic or diagnostic purposes. In a preferred embodiment, the device provides vestibular stimulation sufficient to promote physiological changes in the individual, the changes selected from the group consisting of circadian temperature cycle time shifts, ascorbic acid production, serotonin production, acetylcholine production, histamine production, and heat shock protein production.
Owner:SCION NEUROSTIM LLC
Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases
Owner:FORDHAM UNIVERSITY
Hsp90-inhibiting zearalanol compounds and methods of producing and using same
Zearalanol compounds are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various disorders. Methods of synthesis and use of such compounds are also described and claimed.
Owner:CONFORMAL THERAPEUTICS CORP (US)
Methods for treating cell proliferative disorders and viral infections
The present invention concerns methods for treating cell proliferative diseases, tumors associated with viral infections, and certain viral infections. The disclosed methods use compounds which inhibit heat shock protein 90 proteins. Such methods block Rb negative or deficient cells in the G2 / M phase of the cell cycle and rapidly causes their destruction.
Owner:SLOAN KETTERING INST FOR CANCER RES
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ActiveUS20110195429A1Eliminate needEasy to adaptDisease diagnosisBiological testingSoluble P-SelectinFactor ii
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble p-selectin, protein NOV homolog, soluble epidermal growth factor receptor, netrin-4, haptoglobin, heat shock protein beta-1, alpha-1-antitrypsin, leukocyte elastase, soluble tumor necrosis factor receptor superfamily member 6, soluble tumor necrosis factor ligand superfamily member 6, soluble intercellular adhesion molecule 2, active caspase-3, and soluble platelet endothelial cell adhesion molecule as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Recombinant VSV For The Treatment of Tumor Cells
The present invention relates to compositions and methods for the treatment of tumor and / or malignant and / or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said VSV vectors exhibit greater oncolytic activity against the tumor and / or malignant and / or cancerous cell than a wild-type VSV vector. The present invention also provides methods of making such vectors, host cells, expression systems, and compositions comprising such VSV vectors, and viral particles comprising such VSV vectors. The present invention also provides methods for producing oncolytic activity in a tumor and / or malignant and / or cancerous cell comprising contacting said cell with a VSV vector of the present invention. The present invention also provides methods for suppressing tumor growth comprising contacting said tumor with a VSV vector of the present invention. The present invention also provides methods for eliciting an immune response to a tumor cell in an individual.
Owner:UNIV OF MIAMI
Plasma prekallikrein activation and kallikrein production assay
InactiveUS6913900B2Avoid complicationsInhibit and promote productionCompound screeningApoptosis detectionHigh-molecular-weight kininogenPhosphate ion
A activator for prekallikrein includes isolated, purified, or substantially purified heat shock protein 90, a phosphate ion, and mixtures thereof. The prekallikrein activator is part of an in vitro system for activating prekallikrein in the absence of FXIIa. The system includes the activator, high-molecular weight kininogen, and zinc ions. A method for activating prekallikrein to produce kallikrein in the absence of FXIIa includes mixing prekallikrein with the activator and a composition comprising high molecular weight kininogen and zinc ions. A method for evaluating the activity of a test drug for the production of kallikrein comprises activating prekallikrein and determining the kallikrein produced. The activity (promoting or inhibiting ability) of the tested drug against the production of kallikrein in the absence of FXIIa can be easily measured. The test drug may be an analgesic, anti-allergy, anti-inflammatory drug.
Owner:NIPPON ZOKI PHARM CO LTD
Markers for colorectal cancer
InactiveUS20060188883A1Reduce and eliminate biological activityReduce expressionMicrobiological testing/measurementDisease diagnosisCancer cellBifunctional
Provided are previously uncharacterised markers of cancers, for example colorectal cancers, and uses of these as diagnostic and prognostic markers of cancers, and in particular colorectal cancers. The markers are SEQ ID NO: 1—hnRNP-K; SEQ ID NO:2—HMG-1; SEQ ID NO:3—proteasome subunit alpha type 1; SEQ ID NO:4—bifunctional purine biosynthesis protein; SEQ ID NO:5—ST11; SEQ ID NO:6—annex in IV; SEQ ID NO:7—60 kDa heat shock protein; SEQ ID NO:8—T complex protein 1 beta subunit; SEQ ID NO:9—T complex protein 1 epsilon subunit; SEQ ID NO: 10—mortalin; and SEQ ID NO: 11—TER-ATPase. The invention further provides related methods and materials for the use of the markers in therapeutic intervention in colorectal and other cancers e.g. to specifically target neoplastic cells without causing significant toxicity in healthy tissues, and to provide methods for the evaluation of the ability of candidate therapeutic compounds to modulate the biological activity of cancerous cells from the colon, rectum and other tissues.
Owner:AUVATION +2
Combined energy and topical composition application for regulating the condition of mammalian skin
InactiveUS20080031833A1Improve the situationEasy to superviseCosmetic preparationsBiocidePersonal careSalicylic acid
Method for regulating the condition of mammalian skin comprising the steps of applying a first personal care composition to an area of skin where regulation is desired, wherein the first personal care composition comprises at least one skin care active selected from the group consisting of niacinamide, salicylic acid, peptides, N-acetyl glucosamine, panthenol, butylated hydroxytoluene, N-acyl amino acid compounds, hexamidine, green tea, ascorbyl glucoside, hexanediol, pentanediol, a skin lightening agent, a heat shock protein potentiator, and mixtures thereof, and delivering energy to the area of skin by contacting the skin with an energy delivery device for a treatment period of at least 2½ minutes, wherein the energy delivery device comprises a skin-contacting surface that is controllably heatable to a temperature of from 37° C. to 50° C.
Owner:THE PROCTER & GAMBLE COMPANY
Vestibular stimulation apparatus and associated methods of use
ActiveUS8262717B2Devices for heating/cooling reflex pointsElectrotherapyHistamine ProductionVestibular system
A device and associated method for providing vestibular stimulation to an individual includes active elements positioned on or proximate an ear insert. The active elements include but are not limited to at least one electrode, at least one thermometer, and at least one thermoelectric transducer. The device includes a computerized control module regulating the active elements. The device incorporates an ear insert that allows the active elements to engage the individual's ear canal and therefore access the individual's vestibular system. Vestibular stimulation applied to the individual is customized for directly stimulating desired regions of the brain for therapeutic or diagnostic purposes. In a preferred embodiment, the device provides vestibular stimulation sufficient to promote physiological changes in the individual, the changes selected from the group consisting of circadian temperature cycle time shifts, ascorbic acid production, serotonin production, acetylcholine production, histamine production, and heat shock protein production.
Owner:SCION NEUROSTIM LLC
Skin wrinkle treatment
InactiveUS20190183562A1Promotes collagen productionUltrasound therapyTemperature sensorsCelsius DegreeBiomedical engineering
A method for treating skin may first involve contacting an applicator of a skin heating device with an epidermal layer of the skin. The applicator may be activated to generate high-frequency alternating magnetic fields. The applicator may be used to heat a dermal layer of the skin, with the high-frequency alternating magnetic fields, to a temperature of less than 40 degrees Celsius, to stimulate a release of heat shock protein in the dermal layer to promote collagen generation. The method may also involve limiting heating of the dermal layer of the skin to less than 40 degrees Celsius.
Owner:LIFE CARE MEDICAL DEVICES
Tetrahydroindole and Tetrahydroindazole Derivatives
The invention provides indole and indazole compounds of Formula (I)or pharmaceutically acceptable salts thereof which are useful for treating and / or preventing diseases and / or disorders ameliorated by the inhibition of Heat-Shock Protein 90. The invention further provides pharmaceutical compositions comprising compounds of Formula (I) and methods of preparing compounds of Formula (I).
Owner:SERENEX INC
System and process for treatment of myopia
ActiveUS20170319383A1Preventing and treating myopiaIncrease temperatureUltrasound therapyLaser surgeryCelsius DegreePulse energy
A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed laser beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature up to eleven degrees Celsius to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.
Owner:OJAI RETINAL TECH
Protein cage immunotherapeutics
The present invention provides compositions of heat shock protein cages for use in therapeutic vaccines. The heat shock protein cages of the invention have attached antigen, located either on the interior or exterior of the protein cage, and optionally an adjuvant.
Owner:MONTANA STATE UNIVERSITY
Treatment of Protein Misfolding
InactiveUS20080014191A1Improve biological activityBlock functional activityBiocideOrganic active ingredientsATPaseMedicine
Owner:THE SCRIPPS RES INST
Reagents and methods for smooth muscle therapies
InactiveUS7135453B2Treat or inhibit smooth muscle vasospasmSmooth muscle relaxationFungiNervous disorderSmooth muscleVasospasm
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
Adjuvant immune therapy in the treatment of solid tumors through modulation of signaling pathways following engagement of humoral and cell mediated responses
InactiveUS20020187130A1Evaluating efficacyAccurate assessmentBiocideSaccharide peptide ingredientsAdjuvantWhite blood cell
Owner:KINDNESS GEORGE +2
3,4-diarylpyrazoles and their use in the therapy of cancer
The present invention pertains to the use of certain 3,4-diarylpyazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3 is independently: a C5-20aryl group, and is optionally substituted; Ar4 is independently: a C5-20aryl group, and is optionally substituted; R5 is independently: hydrogen; halo; hydroxyl; ether; formyl; acyl; carboxy; ester; acyloxy; oxycarbonyloxy; amido; acylamido; aminocarbonyloxy; tetrazolyl; amino; nitro; cyano; azido; sulfhydryl; thioether; sulfonamide; C1-7alkyl; C3-20heterocycyl; or C5-20aryl; R<SP>N< / SP> is independently: —H; C1-7alkyl; C3-20heterocycyl; or, C5-20aryl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to such compounds, pharmaceutical compositions comprising such compounds, such compounds for medical use, such compounds use in the treatment of conditions mediated by HSP90, including, for example, cancer, and use of such compounds in the preparation of medicaments for such treatments.
Owner:VERNALIS (R&D) LTD +2
Dihydroxyphenyl isoindolymethanones
InactiveUS7754725B2Preventing huntington protein aggregationFast rebuildBiocideOrganic chemistryStromal tumorMelanoma
Compounds having the formula (I):and in particular, those of subgenus VIIaare disclosed as inhibits or modulators of the activity of the heat shock protein Hsp90. As such they are useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate cancer, lung cancer, gastrointestinal stromal tumor, breast cancer and melanoma.
Owner:OXFORD FINANCE
Chip for gene detection of multiple vibrios at the same time, and detection and use thereof
ActiveCN101475986AEffective guidanceEffectively guide productionMicrobiological testing/measurementMicroorganism based processesForward primerVirulent characteristics
The present invention relates to a detection chip for performing gene detection to various vibrio and its detection and applications. The invention provides 16S rRNA sequences corresponding to each vibrio of vibrio anguillarum, vibrio harveyi, vibrio alginolyticus, vibrio parahaemolyticus, brilliant vibrio and Fisher vibrio; heat shock protein hsp60 probe sequence; virulence gene probe sequence; 16S rRNA forward primer sequence; 16S rRNA reverse primer sequence; heat shock protein hsp60 forward primer sequence; heat shock protein hsp60 reverse primer sequence; virulence gene forward primer sequence and virulence gene reverse primer sequence. The present invention has specific, sensitive and high-throughput features, can simultaneously detect six kinds of bacteria virulence genes, and the invention will effectively guide the production as an important disease early-warning detection method used in clinical diagnosis of aquatic animals.
Owner:YELLOW SEA FISHERIES RES INST CHINESE ACAD OF FISHERIES SCI
Tuberculosis gene vaccine based on T cell epitope as well as preparation method and use thereof
InactiveCN101451145AActivate immune responseDoes not affect the spatial structureAntibacterial agentsGenetic material ingredientsIntramuscular injectionTreating tuberculosis
The invention discloses a tuberculosis gene vaccine based on T cell epitopes, wherein a full-length gene, embedded with four T cell epitope polypeptide genes which come from mycobacterium tuberculosis antigen, of mycobacterium tuberculosis heat shock protein is inserted into a vector. The invention also discloses a method for preparing the vaccine, which comprises the following steps: four T cell epitope genes, namely EAST-6189-228, Ag85A369-405, CFP10162-207 and Ag85B420-459 which come from the mycobacterium tuberculosis antigen are inserted into an HSP65 full-length gene. The invention also discloses application of an ECANS tuberculosis gene vaccine. Through the intramuscular injection of the gene vaccine into an immune mouse, the experiment proves that the vaccine can induce a specific antibody which aims at a plurality of tuberculosis antigens to response, can induce stronger tuberculosis specific killing response, can induce Th1 immune response at the same time, secrete high-level IFN gamma, and is a good vaccine for preventing and treating tuberculosis.
Owner:FUDAN UNIV
Novel Heat Shock Protein 20-Related Polypeptides and Uses Therefor
InactiveUS20080132443A1Inhibiting smooth muscle cell proliferationInhibit migrationNervous disorderPeptide/protein ingredientsHeat shock proteinDrug
Owner:ARIZONA STATE UNIVERSITY
Methods for Promoting Wound Healing and/or Reducing Scar Formation
InactiveUS20100009903A1Promote wound healingReduce scarsPeptide/protein ingredientsMetabolism disorderWound healingScars
The present invention provides methods for promoting wound healing and / or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.
Owner:ARIZONA STATE UNIVERSITY
Compositions and methods for modulation of immune responses
The present invention relates to a novel mechanism for modulation of immune response. More closely, the present invention relates to modulation of CD94 / NKG2 receptor yfunction by HLA-E+bound peptides causing either inhibition or absence of inhibition of said receptors. In a preferred embodiment the invention relates to HLA-E binding hsp (heat shock protein) 60 peptides.
Owner:PEPGEN CORP
Recombinant protein vaccine for preventing and treating human prostata cancer
The recombinant protein vaccine is a fusion protein formed from connection of BCG vaccine heat shock protein 65 with 1-5 copies of human prostatic specific antigen cytotoxin T lymphocyte polyepitope,in which the single-copy polypeptide of said human prostatic specific antigen cytotoxin T lymphocyte polyepitope possesses amino acid sequence showed by SEQ ID NO:2, and the double single-copy polypeptide of the human prostatic specific antigen dcytotoxin T lymphocyte polyeptope possesses amino acid sequence showed by SEQ ID NO:4. After it is applied in human body, it can effectively prevent and cure carcinoma of prostate. Said invention also provides the gene for coding said two kinds of recombinant protein vaccines.
Owner:BEIJING HYDVAX BIOTECH
Dihydroxyphenyl isoindolylmethanones
InactiveUS20070259886A1Preventing huntington protein aggregationEffective treatmentBiocideOrganic chemistryStromal tumorMelanoma
Compounds having the formula (I): and in particular, those of subgenus VIIa are disclosed as inhibits or modulators of the activity of the heat shock protein Hsp90. As such they are useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate cancer, lung cancer, gastrointestinal stromal tumor, breast cancer and melanoma.
Owner:OXFORD FINANCE
Reagents and methods for smooth muscle therapies
InactiveUS20060035814A1Treat or inhibit smooth muscle vasospasmSmooth muscle relaxationFungiNervous disorderSmooth muscleVasospasm
The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com